Imipenem/cilastatin use in newborn infants Yenidogan doneminde imipenem/silastatin kullanimi
Cocuk Sagligi ve Hastaliklari Dergisi, cilt.40, sa.4, ss.513-518, 1997 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 40 Sayı: 4
- Basım Tarihi: 1997
- Dergi Adı: Cocuk Sagligi ve Hastaliklari Dergisi
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.513-518
- Anahtar Kelimeler: Imipenem/cilastin, Newborn infant
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet
Özet
In our study we evaluated the safety of using imipenem/cilastin during the neonatal period. The cases which were treated with imipenem/cilastin because of sepsis and/or pneumonia were included in this study. The gestational ages of the cases and their birth weights, risk factors, types of infection, bacteria responsible for the infections, and side effects of imipenem/cilastatin were retrospectively noted. Between January 1993 and December 1995, we used imipenem/cilastin in 51 newborns with invasive infection. Eighty percent of cases (41/51) were premature. Assisted ventilation and umbilical catheterization were needed in 71% (36/51) and 65% (33/51) of the cases, respectively. Thirty-two percent of the cases (16/51) died, with Klebsiella pneumonia being the most responsible bacteria. No incidence of diarrhea, thrombophlebitis or thrombocytosis was observed. Six cases had eosinophilia. Three cases had elevated hepatic enzymes, two cases with elevated urea and creatinin levels. Two cases had convulsions. Twenty nine percent (15/51) of the cases had Candida colonization. These results show that imipenem/cilastatin is effective for use during the neonatal period in cases with invasive infection. However, because of the still insufficient information regarding the safety of its use during the neonatal period and the very high colonization rate with Candida albicans, it must be used carefully.